8-K: Artiva Biotherapeutics Appoints Alison Moore to Board of Directors

Artiva Biotherapeutics has appointed Alison Moore, Ph.D., as a Class III director and member of the Technical Operations Committee, effective October 21, 2024.

Summary

• Artiva Biotherapeutics has appointed Alison Moore, Ph.D., to its Board of Directors as a Class III director, with her term expiring at the 2027 annual meeting of stockholders.
• Dr. Moore will also serve on the Technical Operations Committee of the Board.
• She has extensive experience in the biotechnology and pharmaceutical industries, including roles at Codexis, Allogene Therapeutics, and Amgen.
• Dr. Moore will receive an annual cash retainer of $40,000 for her service on the Board and $15,000 for her service on the Technical Operations Committee.
• She was also granted an option to purchase 27,500 shares of the company's common stock, with one-third vesting immediately and the remainder vesting over two years.
• Dr. Moore will also receive annual option grants for 13,750 shares, vesting either one year from the grant date or at the next annual stockholder meeting.
• All options will vest fully upon a change in control of the company.

Sentiment

Score: 8

Explanation: The appointment of an experienced director is a positive development for the company, suggesting a strengthening of its leadership and technical expertise. The compensation package is also standard and aligns interests.

Positives

• The appointment of Alison Moore, Ph.D., brings significant industry experience to Artiva's Board of Directors.
• Dr. Moore's background includes leadership roles at Codexis, Allogene Therapeutics, and Amgen, which should benefit the company.
• The compensation package for Dr. Moore includes both cash retainers and stock options, aligning her interests with those of the shareholders.
• The vesting schedule for the stock options encourages long-term commitment from Dr. Moore.

Risks

• There are no specific risks mentioned in this document.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• The Board of Directors appointed Alison Moore, Ph.D., upon recommendation of the Nominating and Corporate Governance Committee.

Industry Context

The appointment of a seasoned executive like Dr. Moore, with experience at major biotech and pharmaceutical companies, is a positive signal for Artiva Biotherapeutics, indicating a focus on strengthening its leadership team and technical capabilities. This is a common practice in the biotech industry as companies mature and seek to advance their pipelines.

Comparison to Industry Standards

• The compensation package for Dr. Moore, including cash retainers and stock options, is consistent with industry standards for non-employee directors at publicly traded biotech companies.
• Companies like Allogene Therapeutics and Amgen, where Dr. Moore previously held leadership positions, often use similar compensation structures to attract and retain experienced board members.
• The vesting schedule for the stock options is also typical, designed to align the director's interests with the long-term success of the company.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of Dr. Moore positively, as it strengthens the company's leadership and technical expertise.
• Employees may benefit from Dr. Moore's experience and guidance.
• The appointment does not have a direct impact on customers, suppliers, or creditors.

Next Steps

• Dr. Moore will begin her service on the Board and the Technical Operations Committee.
• She will receive her initial stock option grant and begin vesting according to the schedule.
• She will receive annual stock option grants at each annual meeting of stockholders.

Key Dates

Keywords

Board of Directors, director appointment, biotechnology, pharmaceutical, stock options, corporate governance, executive compensation, technical operations, Artiva Biotherapeutics